Table 17 (abstract P234). Characteristics of patients who received live-attenuated vaccines
From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two
Patient | Disease | Biological | Other medication | Vaccination | Adverse events | Flare |
|---|---|---|---|---|---|---|
1 | CINCA | Anakinra 1.5 mg/kg/day | Methyl-prednisolone | MMR booster | - | - |
2 | MKD | Anakinra 1.4 mg/kg/day | - | MMR booster | - | - |
3 | FMF | Canakinumab 4 mg/kg/monthly | Prednisone Colchicine | MMR booster | - | FMF attack after 1 week |
4 | sJIA | Canakinumab 4 mg/kg/2 months | Prednisone Methotrexate Ibuprofen (if necessary) | MMR booster | Pneumonia 1 week after vaccination | Fever and rash attacks |
5 | sJIA | Anakinra 1.7 mg/kg/2 days | Methotrexate Indometacine | MMR booster | - | A bit more exanthema due to stop of anakinra |
6 | sJIA | Anakinra 40 mg/3 days | - | MMR booster | - | - |
7 | sJIA | Tocilizumab 132 mg/14 days | Prednisone Indometacine | Varicella zoster (first vaccine) | - | Exanthema, subfebrile temperature, malaise |
8 | sJIA | Anakinra 4 mg/kg/day | Prednisone Methotrexate Leflunomide Thalidomide | Varicella zoster (booster) | Hospitalization due to varicella infection and immune-suppression, treatment with acyclovir | - |
9 | sJIA | Tocilizumab 12 mg/kg/monthly | Prednisone Ibuprofen (if necessary) | Oral polio vaccine | Diarrhea | - |